| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/04/1995 | WO1995011671A1 Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients |
| 05/04/1995 | WO1995011668A1 Gelatin capsule fill able to foam |
| 05/04/1995 | WO1995011663A1 Proteinaceous materials and formulations for sunburn cell protection |
| 05/04/1995 | WO1995006077A3 Polymeric matrices and their uses in pharmaceutical compositions |
| 05/04/1995 | DE4404990C1 Process for producing a sterile prednisolone gel |
| 05/04/1995 | DE4343431C1 Cosmetic and/or pharmaceutical compositions |
| 05/04/1995 | CA2203916A1 Proteinaceous materials and formulations for sunburn cell protection |
| 05/04/1995 | CA2174943A1 A new ribosome-inactivating protein isolated from the plant bryonia dioica |
| 05/04/1995 | CA2174777A1 Gelatin capsule fill able to foam |
| 05/04/1995 | CA2174210A1 Method of controlled genetic transformation of an animal mammary gland and a device for introducing genetic material into the mammary duct of an animal mammary gland |
| 05/04/1995 | CA2173467A1 A stable pharmaceutical composition of terfenadine and ibuprofen |
| 05/04/1995 | CA2134745A1 Glycosaminoglycan-synthetic polymer conjugates |
| 05/04/1995 | CA2134744A1 Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
| 05/03/1995 | EP0650735A2 Kit and method for pretargeting |
| 05/03/1995 | EP0650730A1 Rapamycin formulations for oral administration |
| 05/03/1995 | EP0650729A1 Rapamycin formulations for IV injection |
| 05/03/1995 | EP0650721A1 Cyclosporin soft capsule |
| 05/03/1995 | EP0650596A1 Compositions and methods for regulating cellular signal transducing systems |
| 05/03/1995 | EP0650373A1 Sustained release alginate fibre and process for the preparation thereof. |
| 05/03/1995 | EP0650371A1 Covalent polar lipid-peptide conjugates for biological targeting |
| 05/03/1995 | EP0650370A1 Methods and compositions for targeting specific tissue |
| 05/03/1995 | EP0650366A1 Compositions and methods for treating wounds |
| 05/03/1995 | EP0650354A1 Solid and liquid solutions of drugs which are not readily soluble in water |
| 05/03/1995 | EP0650353A1 Palatable pharmaceutical compositions |
| 05/03/1995 | EP0586488B1 Pharmaceutical enema preparation |
| 05/03/1995 | EP0569541B1 Growth factor containing matrix for the treatment of cartilage lesions |
| 05/03/1995 | EP0458949B1 Stabilization of k1k2p pro |
| 05/03/1995 | EP0456724B1 Composition and method for treating benign prostatic hypertrophy |
| 05/03/1995 | CN1102095A Long-acting androgen preparation-undecylic acid testis injection |
| 05/03/1995 | CN1102094A Granular preparation |
| 05/02/1995 | US5412089 Antitumor, antiviral |
| 05/02/1995 | US5412074 Silcone modified proteins |
| 05/02/1995 | US5412072 Water soluble high molecular weight polymerized drug preparation |
| 05/02/1995 | US5411993 Anti-inflammatory, stable aqueous preparation comprising azulene sodium sulfonate and polyhydric alcohol |
| 05/02/1995 | US5411952 Ocular cyclosporine composition |
| 05/02/1995 | US5411951 Prolonged release of biologically active somatotropin |
| 05/02/1995 | US5411947 converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside |
| 05/02/1995 | US5411884 Monoclonal antibody L53 which recognizes a human tumor-associated antigen |
| 05/02/1995 | US5411744 Silicone vesicles and entrapment |
| 05/02/1995 | US5411740 Transdermal administration of oxybutynin |
| 05/02/1995 | US5411738 Maintaining lidocaine intradermally at a concentration sufficient to induce analgesia |
| 05/02/1995 | US5411737 Slow release syneresing polymeric drug delivery device |
| 05/02/1995 | CA1335408C Process for treating talc |
| 04/28/1995 | CA2109337A1 Polypeptides and polynucleotides related to the pa-i lectin of pseudomonas aeruginosa |
| 04/27/1995 | WO1995011311A1 METHOD OF BINDING MATERIAL TO THE β-AMYLOID PEPTIDE |
| 04/27/1995 | WO1995011289A1 Stabilisation of polyunsaturates |
| 04/27/1995 | WO1995011225A1 Use of terminal group capped fatty acid amide alkoxylates |
| 04/27/1995 | WO1995011043A1 Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation |
| 04/27/1995 | WO1995011039A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORINE A AND α-TOCOPHEROL |
| 04/27/1995 | WO1995011024A1 Picosulphate dosage form |
| 04/27/1995 | WO1995011015A1 Composition and method for treating blood vessel disorders of the skin using vitamin k |
| 04/27/1995 | WO1995011010A1 Methods and compositions for microencapsulation of antigens for use as vaccines |
| 04/27/1995 | WO1995011006A1 Highly active sulphonyl urea preparations exhibiting rapid or controlled release of the active substance, and method of producing them |
| 04/27/1995 | WO1995010999A1 Novel composition |
| 04/27/1995 | CA2174666A1 Composition and method for treating blood vessel disorders of the skin using vitamin k |
| 04/27/1995 | CA2174538A1 Base for sustained-release preparation, sustained-release preparation, and process for producing the preparation |
| 04/27/1995 | CA2174501A1 Method of binding material to the .beta.-amyloid peptide |
| 04/27/1995 | CA2174110A1 Stabilisation of polyunsaturates |
| 04/27/1995 | CA2173366A1 Highly active sulphonyl urea preparations exhibiting rapid or controlled release of the active substance, and method of producing them |
| 04/27/1995 | CA2173335A1 Use of terminal group capped fatty acid amide alkoxylates |
| 04/27/1995 | CA2134293A1 Pharmaceutical preparation for the parenteral, enteral and dermal administration of virtually insoluble medicinal substances and a process for its production |
| 04/26/1995 | EP0649854A1 Bisconjugates comprising two saccharides and a spacer |
| 04/26/1995 | EP0649662A1 Biodegradable implant precursor |
| 04/26/1995 | EP0649660A2 Pharmaceutical composition for parenteral, enteral and dermal administration of essentially insoluble drugs and process for their preparation |
| 04/26/1995 | EP0649659A1 Rapamycin formulation for IV injection |
| 04/26/1995 | EP0649655A1 Injectable solutions containing anti-ulcer benzimidazoles and amides |
| 04/26/1995 | EP0649653A1 Use of partially methylated beta-cyclodextrins as absorption enhancers in the manufacture of pharmaceutical compositions for the transdermal administration of active agents |
| 04/26/1995 | EP0649650A1 Bioadhesive pharmaceutical composition for controlled release of drugs |
| 04/26/1995 | EP0649649A2 Colloidal, dispersible formulations of active substances |
| 04/26/1995 | EP0649523A1 Bioassay for the screening of ion channel active molecules |
| 04/26/1995 | EP0649312A1 Anthracycline conjugates, their preparation and their use as antitumor agents |
| 04/26/1995 | EP0649302A1 Therapeutic and diagnostic use of modified polymeric microcapsules |
| 04/26/1995 | EP0649301A1 Cold cream used in oxidative hair dyes and hair bleaching compositions. |
| 04/26/1995 | EP0649274A1 Aqueous compositions comprising an organic peroxiacid |
| 04/26/1995 | EP0538302B1 Reduction or prevention of skin irritation by drugs |
| 04/26/1995 | EP0526481B1 The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| 04/26/1995 | EP0521070B1 Aqueous suspension preparation for injection, method for producing the same and use thereof for producing pain relief |
| 04/26/1995 | EP0515510B1 Hydroquinone amino-acid esters, method of preparation, and pharmaceutical or cosmetic compositions containing them |
| 04/26/1995 | CN1101841A Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof |
| 04/25/1995 | US5410025 Passing polyclonal material through anion exchange column to absorb immunoglobulins, eluting low anticomplementary fraction with sodium chloride gradient and buffer under acidic conditions |
| 04/25/1995 | US5410016 A curable additional polymerizable macromolecular monomers comprising at least one water soluble region, at least one degradable, hydrolyzable region and free radical polymerizable end groups; drug delivery |
| 04/25/1995 | US5409917 Topical treatment of acne with cephalosporins |
| 04/25/1995 | US5409908 Complexing urushiols |
| 04/25/1995 | US5409704 Administering in the treatment of gram negative pneumonia |
| 04/25/1995 | US5409699 Compositions containing glycosylated molecules having human tissue type plasminogen activator enzymatic activity |
| 04/25/1995 | US5409697 A stable microbiocides in aqueous solution comprising polyvinylpyrrolidone, iodine liberated from hydroiodic acid or an alkali metal iodide; antiseptic |
| 04/25/1995 | CA2020877C Stable tretinoin emulsified cream formulations |
| 04/25/1995 | CA1335350C Liposome composition and production thereof |
| 04/20/1995 | WO1995010624A1 Endosomolytically active particles |
| 04/20/1995 | WO1995010307A1 Radiation sensitization using texaphyrins |
| 04/20/1995 | WO1995010306A1 Prophylaxis in the parenteral administration of particulate dispersions |
| 04/20/1995 | WO1995010304A1 Polymer-bound camptothecin derivatives |
| 04/20/1995 | WO1995010302A1 Cellular and serum protein anchors and conjugates |
| 04/20/1995 | WO1995010301A1 Immunological tolerance-inducing agent |
| 04/20/1995 | WO1995010274A1 Aqueous pharmaceutical composition |
| 04/20/1995 | WO1995010265A1 Therapeutic delivery compositions and methods of use thereof |
| 04/20/1995 | WO1995010259A1 Free flowing emulsion concentrate |
| 04/20/1995 | WO1995010258A1 Inhibition of urinary calculi growth |
| 04/20/1995 | WO1995010185A1 Superoxide dismutase and mimetics thereof |
| 04/20/1995 | CA2622018A1 Cellular and serum protein anchors and conjugates |